CymaBay Therapeutics is a biopharmaceutical company dedicated to the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on Type-2 diabetes. The company has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. CymaBay Therapeutics's clinical program is focused on developing next-generation insulin sensitizers that lower blood glucose without the serious safety and tolerability issues associated with currently marketed products.
Tel: 510-293-8800 www.cymabay.com
- Mission to transform the treatment of Type-2 diabetes and other metabolic disorders
- Strategy to discover and develop promising therapies for metabolic diseases to address significant unmet medical needs in large markets